Articles related to ADVERSE EVENTS

With varying incidence rates of paradoxical adipose hypertrophy (PAH) and increasing reports of disfigurement, CoolSculpting’s non-invasive fat reduction procedure warrants careful examination. Physicians are encouraged to delve into the research and counsel patients thoroughly on potential risks and alternative approaches.

Understanding the Effects of Drugs with Depressive Symptom Side Effects on Patients with MDD Learn more about the complex interaction between the usage of specific drugs and the severity of depressive symptoms in people with major depressive disorder (MDD).

The number of patients who get immune-related adverse events (irAEs) will increase as the reasons for immune checkpoint inhibitors (ICI) therapy broaden. Because irAEs can progress and result in catastrophic or fatal results, early detection and therapy are crucial. Systemic corticosteroids and immunosuppressive medications are crucial to treating moderate to severe irAEs, although withdrawal of ICIs is often advised for high-grade occurrences. Preventing irAEs, treating corticosteroid-refractory instances, and evaluating whether ICIs may be safely reintroduced after the incidence of severe irAEs are all challenges. The ongoing search for predictive biomarkers of irAEs is critical for informing treatment strategies that maximize the clinical advantages of ICIs while lowering the risk of toxicities.

After completing this CE activity, optometrists who work with cancer patients should be better able to recognize the potential ocular side effects of targeted cancer therapies, monitor patients on these drugs for potential ocular adverse events, consult with specialists as needed, and educate their patients about how these medications may affect their eye health.

According to the findings of the study, gabapentin should not be used on a regular basis. Individualization is required, based on the type of pain and the risk of delirium. If gabapentin is used to control postoperative pain, it must be closely monitored for the development of delirium. Low-dose opioids, along with nonpharmacologic pain management strategies such as postoperative physical therapy and mobilization, can still be used safely in the study population. Rather than relying on a single medication, a more holistic approach to postoperative pain control in the hospital setting is required.

Although immune therapies, such as immune checkpoint inhibitors (ICIs), have significantly improved cancer outcomes, these therapies can also cause off-target tissue damage and response variability. The host microbiome affects ICI responsiveness and risk of immune-related adverse effects (irAEs), according to numerous lines of evidence. These developments show the possibility to control microbiome elements to improve the success of ICI because the microbiome is manipulable.